Linear scleroderma is a form of localized scleroderma where the skin hardens and thickens in a band-like pattern, typically running along an arm, leg, or across the forehead. Unlike systemic scleroderma, which can affect internal organs throughout the body, linear scleroderma primarily targets the skin and the tissues beneath it, including muscle and bone. It is the most common form of localized scleroderma in children, though it can appear at any age.
How Linear Scleroderma Differs From Other Types
Scleroderma is a broad term covering several conditions that involve skin hardening. Systemic scleroderma affects blood vessels, internal organs, and the digestive tract and carries risks like lung scarring and high blood pressure in the arteries between the heart and lungs. Linear scleroderma is a localized form, meaning it stays in one area rather than spreading throughout the body. The fibrosis follows a line, often along a limb or one side of the face, rather than appearing in patches (as in morphea, another localized type).
There are two notable subtypes that affect the head and face. “En coup de sabre” produces a band of hardened, indented skin running vertically down the forehead or scalp, resembling a scar from a saber wound. This subtype carries more serious risks because it can involve the eyes, mouth, and brain. Parry-Romberg syndrome is a closely related condition that causes progressive shrinking of the skin, fat, and sometimes bone on one side of the face. Distinguishing between these two conditions matters because their complications and monitoring needs differ.
What Causes the Skin to Harden
The hardening in linear scleroderma comes from overproduction of collagen and other structural proteins by cells called fibroblasts. Normally, fibroblasts produce just enough collagen to maintain healthy connective tissue. In scleroderma, abnormal signaling between blood vessel cells, immune cells, and fibroblasts pushes the fibroblasts into overdrive. They churn out excessive amounts of collagen and related proteins, which accumulate in the skin and deeper tissues.
This process is driven partly by reduced blood flow and low oxygen levels in the affected tissue. Growth factors, particularly one called TGF-beta, act as chemical signals that keep fibroblasts activated. Some fibroblasts also transform into a more aggressive cell type that produces collagen at an even higher rate. The result is progressive thickening and tightening of the skin, and in many cases, the fibrosis extends into the fat, muscle, and even bone beneath it.
The exact trigger that starts this cascade isn’t fully understood, but it appears to involve an immune system that mistakenly attacks the body’s own tissues. Linear scleroderma is not contagious, not caused by injury, and not directly inherited, though having family members with autoimmune conditions may increase risk.
Who Gets Linear Scleroderma
Linear scleroderma most often appears in childhood and adolescence. Incidence rises notably after age 10, and prevalence climbs from about 1.7 per million in children under 6 to 26.8 per million in those between 12 and 18. The average age at diagnosis is around 11 to 12 years, though adults develop it as well.
Girls and women are affected roughly two to three times more often than boys and men. In pediatric studies, about 69 to 72% of patients are female. The condition occurs across all ethnic groups but has been most frequently identified in white patients, who make up about 60 to 69% of cases in U.S. studies. Whether this reflects true biological differences or disparities in diagnosis and healthcare access isn’t entirely clear.
Signs and Symptoms
The earliest signs are often subtle: a streak of discolored skin, mild swelling, or itchiness along a limb or on the forehead. Over weeks to months, the affected skin becomes firmer and tighter. It may look shiny and feel waxy. The color can shift, becoming lighter or darker than the surrounding skin.
What sets linear scleroderma apart from other skin conditions is how deep it can go. The fibrosis doesn’t stop at the skin surface. It can extend into the fat layer, the connective tissue wrapping the muscles (fascia), and the muscles themselves. When it affects a growing child’s limb, the hardened tissue can restrict normal bone growth on that side, leading to one arm or leg being noticeably shorter than the other. Joint contractures, where fibrosis locks a joint in a bent position, can become severe enough to limit walking or prevent straightening the elbow.
In one surgical case series, seven children with linear scleroderma needed reconstructive surgery because fibrosis had caused debilitating soft tissue contractures that prevented them from walking or fully extending their elbows. Even after successful reconstruction that restored range of motion in most patients, all had residual limb deformity and more than half still had limb length differences.
Craniofacial Complications
When linear scleroderma appears on the head or face (the en coup de sabre subtype), the stakes are higher. The fibrosis can affect structures beneath the skull, leading to neurological problems including seizures, headaches, dizziness, difficulty with coordination, and cognitive decline. One documented case involved a patient diagnosed at age 12 who, decades later, developed worsening ataxia (loss of coordination), cranial nerve problems, and eventually generalized seizures and behavioral changes.
Eye abnormalities are another concern with craniofacial involvement. These can range from inflammation inside the eye to changes in the eyelid or surrounding tissue. Because neurological symptoms sometimes appear years or even decades after the skin changes first develop, ongoing monitoring is important for anyone with linear scleroderma on the head or face.
How It Is Diagnosed
There is no single blood test that confirms linear scleroderma. Diagnosis relies primarily on physical examination: the characteristic band-like pattern of skin thickening, along with changes in skin color and texture. A skin biopsy, where a small sample of affected tissue is examined under a microscope, can confirm the presence of excess collagen and inflammation in the deeper skin layers.
For craniofacial cases, brain imaging (usually MRI) is used to check for changes in the brain tissue beneath the affected skin. Eye exams help catch early signs of ocular involvement. In limb cases, X-rays or other imaging can reveal bone involvement or growth differences between the affected and unaffected sides.
Doctors use a standardized tool called the Localized Scleroderma Cutaneous Assessment Tool (LoSCAT) to track the condition over time. It evaluates skin lesions across 18 body sites, scoring both active disease signs (new lesions, redness, skin thickness) and accumulated damage separately. This distinction matters because active disease can be treated, while existing damage requires a different management approach.
Treatment Options
The goal of treatment is to stop the inflammatory and fibrotic process before it causes permanent damage. For linear scleroderma that is actively progressing or involves deeper tissues, the standard approach combines immunosuppressive medications with anti-inflammatory therapy.
Methotrexate, taken once weekly, is the most commonly used medication. It works by calming the overactive immune response that drives fibrosis. It’s often started alongside a course of corticosteroids to bring inflammation under control more quickly. This combination has the strongest evidence base for slowing or halting disease progression.
UVA1 phototherapy, a specific type of ultraviolet light treatment, is another option that can soften hardened skin. It’s sometimes used alongside medication or on its own for milder cases. For surface-level skin involvement, topical medications applied directly to the affected area may be sufficient, though linear scleroderma that extends into deeper tissues almost always requires systemic (whole-body) treatment.
Starting treatment early makes a meaningful difference. Research on children with localized scleroderma found that delays in beginning systemic treatment were associated with longer periods of active disease and higher relapse rates.
Long-Term Outlook
Most people with linear scleroderma eventually reach complete remission, where the disease stops progressing. In a long-term follow-up study of children with localized scleroderma, only 12.5% still had active disease after more than 10 years, and all of those were the linear subtype. That’s encouraging overall but highlights that linear scleroderma can be more persistent than other localized forms.
Relapse is a real possibility. About 22% of patients experienced at least one flare, with the first relapse typically occurring around 20 months after stopping treatment. This means that even after the disease appears inactive, periodic check-ups remain valuable for catching any return of activity early.
The permanent effects of linear scleroderma depend heavily on where it occurred and how deep the fibrosis went before treatment began. Skin discoloration and texture changes often persist even after the disease is no longer active. Limb length differences and joint contractures in children may require physical therapy, orthopedic intervention, or in severe cases, reconstructive surgery. For craniofacial cases, cosmetic concerns from facial asymmetry or forehead indentation can be addressed with surgical or injectable techniques once the disease has been stable for an extended period.